scholarly journals The First Clinical Use of a Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E7 Oncogene Oral Vaccine: A Phase I Safety and Immunogenicity Trial in Healthy Women Volunteers

2019 ◽  
Vol 19 (2) ◽  
pp. 717-727 ◽  
Author(s):  
Amir Hossein Mohseni ◽  
Sedigheh Taghinezhad-S ◽  
Hossein Keyvani
2002 ◽  
Vol 68 (2) ◽  
pp. 917-922 ◽  
Author(s):  
L. G. Berm�dez-Humar�n ◽  
P. Langella ◽  
A. Miyoshi ◽  
A. Gruss ◽  
R. Tamez Guerra ◽  
...  

ABSTRACT The E7 protein of human papillomavirus type 16 was produced in Lactococcus lactis. Secretion allowed higher production yields than cytoplasmic production. In stationary phase, amounts of cytoplasmic E7 were reduced, while amounts of secreted E7 increased, suggesting a phase-dependent intracellular proteolysis. Fusion of E7 to the staphylococcal nuclease, a stable protein, resulted in a highly stable cytoplasmic protein. This work provides new candidates for development of viral screening systems and for oral vaccine against cervical cancer.


Vaccine ◽  
2015 ◽  
Vol 33 (13) ◽  
pp. 1586-1595 ◽  
Author(s):  
Shanguang Guo ◽  
Weiwei Yan ◽  
Sean P. McDonough ◽  
Nengfeng Lin ◽  
Katherine J. Wu ◽  
...  

Vaccine ◽  
2001 ◽  
Vol 19 (30) ◽  
pp. 4276-4286 ◽  
Author(s):  
Wolfram Osen ◽  
Tanja Peiler ◽  
Peter Öhlschläger ◽  
Sandra Caldeira ◽  
Stefan Faath ◽  
...  

2013 ◽  
Vol 108 (2) ◽  
pp. 450-460 ◽  
Author(s):  
J E Hanning ◽  
H K Saini ◽  
M J Murray ◽  
S van Dongen ◽  
M P A Davis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document